GlassScriptPhysician profile
Katherine Kivela
NPI 1609446905
$2,292.76
in general payments reported to CMS, 2019-2025
24 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.17 · 2022: $288 · 2023: $268 · 2024: $449 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.35 | 2022-2025 | |
| Novo Nordisk INC | $260.13 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $219.79 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $201.86 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.96 | 2021-2025 | Jardiance |
| Abbott Laboratories | $134.32 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $122.88 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $95.25 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $77.60 | 2024-2025 | |
| Daiichi Sankyo INC. | $49.51 | 2024-2025 | Injectafer |
| Pfizer INC. | $37.85 | 2025 | |
| Lundbeck LLC | $31.77 | 2025 | Rexulti |
| Globus Medical, INC. | $29.74 | 2025 | Senza |
| Astellas Pharma US INC | $25.67 | 2025 | Veozah |
| Verona Pharma, INC. | $23.50 | 2025 | Ohtuvayre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.30 | 2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $21.78 | 2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $19.36 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $19.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2025 | Eliquis |
| Agios Pharmaceuticals, INC. | $17.31 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2022 | |
| Amgen INC. | $14.31 | 2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $14.21 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Kivela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.